IGC Pharma PFO gets 2.0M shares for debt swap
IGC Pharma director and principal financial officer Claudia Grimaldi acquired 2,048,378 shares of common stock in a debt-for-equity swap.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
IGC Pharma director and principal financial officer Claudia Grimaldi acquired 2,048,378 shares of common stock in a debt-for-equity swap. The shares were obtained at $0.27 per share in a private placement in exchange for cancellation of $553,062 of indebtedness owed to her by the company.
Following this transaction, she directly holds 3,421,092 common shares. The new shares are restricted securities under Rule 144 and were issued under a Section 4(a)(2) private placement exemption, with approval by disinterested directors and the Audit Committee for Rule 16b-3 purposes.
Insider Trade Summary
Grant/Award: 2,048,378 shares
Grant/Award
1 txn
Insider
GRIMALDI CLAUDIA
Role
PFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,048,378 | $0.27 | $553K |
Holdings After Transaction:
Common Stock — 3,421,092 shares (Direct)
Footnotes (1)
- F1. Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $553,062 of outstanding indebtedness owed by the Issuer to the Reporting Person. The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3.
Key Figures
Shares acquired: 2,048,378 shares
Issue price: $0.27 per share
Debt cancelled: $553,062
+3 more
6 metrics
Shares acquired
2,048,378 shares
Common stock granted in private placement on June 30, 2026
Issue price
$0.27 per share
Price for common stock issued in debt-for-equity swap
Debt cancelled
$553,062
Indebtedness from IGC Pharma to Claudia Grimaldi exchanged for shares
Post-transaction holdings
3,421,092 shares
Total common shares directly held after acquisition
Regulatory exemption
Section 4(a)(2)
Private placement exemption from registration under Securities Act of 1933
Restricted status
Rule 144 restricted securities
Resale of acquired shares subject to Rule 144 conditions
Key Terms
private placement, restricted securities, Rule 144, Section 4(a)(2) of the Securities Act of 1933, +2 more
6 terms
private placement financial
"Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $553,062 of outstanding indebtedness"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
restricted securities regulatory
"The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144"
Restricted securities are shares or other investment instruments that come with legal or contractual limits on when and how they can be sold, like stock given to founders or bought in a private offering. Think of them as assets in a locked box that can’t be freely traded until certain conditions — such as a waiting period, company registration, or specific approvals — are met. For investors this matters because restricted securities are less liquid and can affect timing, price, and perceived value when they eventually enter the market.
Rule 144 regulatory
"are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Section 4(a)(2) of the Securities Act of 1933 regulatory
"were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933"
Audit Committee financial
"The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Rule 16b-3 regulatory
"approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What approvals did the IGC (IGC) debt-for-equity transaction for Claudia Grimaldi receive?
The transaction was approved in advance by IGC Pharma’s disinterested directors and its Audit Committee. The Form 4 notes that Grimaldi was recused from the approval process and that the approval was for purposes of Rule 16b-3 under securities regulations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
